Financial Performance - The company's operating revenue for Q1 2025 reached ¥1,562,489,599.05, representing an increase of 800.98% compared to ¥173,420,445.95 in the same period last year[6]. - Net profit attributable to shareholders was ¥376,144,390.86, a significant turnaround from a loss of ¥218,754,276.47 in the previous year[6]. - The company reported a substantial investment income of ¥689,616,725.66 in Q1 2025, recovering from a loss of ¥867,995,651.16 in Q1 2024[32]. - Net profit for Q1 2025 was ¥378,831,579.15, compared to a net loss of ¥216,647,616.36 in Q1 2024, indicating a turnaround in profitability[33]. - The company reported a total comprehensive income of ¥486,988,552.83 for Q1 2025, compared to ¥144,090,693.28 in Q1 2024[33]. - The company achieved a net cash inflow from financing activities of ¥725,453,889.13 in Q1 2025, compared to ¥1,179,492,480.52 in Q1 2024[37]. - The company’s total expenses for Q1 2025 were ¥1,065,835,667.53, significantly higher than ¥473,490,650.96 in Q1 2024[32]. Cash Flow and Liquidity - The net cash flow from operating activities improved to ¥729,755,962.41, compared to a negative cash flow of ¥1,018,886,181.06 in the same period last year[6]. - Cash and cash equivalents increased by 109.80% to approximately ¥32.34 billion, primarily due to the consolidation of newly acquired subsidiaries[16]. - The ending cash and cash equivalents balance for Q1 2025 was 27,133,103,669.78, compared to 17,904,491,198.65 in Q1 2024, reflecting a strong liquidity position[51]. - Cash inflow from operating activities totaled 6,090,821,303.91 in Q1 2025, down from 10,606,218,397.82 in Q1 2024[50]. - Cash outflow from operating activities decreased to 5,199,391,762.25 in Q1 2025 from 11,836,775,839.01 in Q1 2024[50]. - The company reported a net interest income of -¥12.39 million for Q1 2025, an improvement from -¥33.35 million in Q1 2024[45]. Assets and Liabilities - Total assets increased by 79.53% to ¥174,517,507,696.98 from ¥97,208,143,600.76 at the end of the previous year[8]. - The total liabilities of the company as of March 31, 2025, amounted to RMB 123.54 billion, up from RMB 78.26 billion, reflecting an increase of around 58%[27][28]. - Total assets increased to ¥128.04 billion as of March 31, 2025, from ¥95.14 billion as of December 31, 2024, representing a growth of approximately 34.5%[41]. - Total liabilities rose to ¥78.29 billion as of March 31, 2025, compared to ¥77.05 billion as of December 31, 2024, indicating a slight increase of about 1.6%[42]. Shareholder Information - The number of ordinary shareholders reached 101,094, indicating a broadening shareholder base[18]. - The top ten shareholders collectively hold 56.73% of the company's shares, with Wuxi Guolian Development Group holding the largest stake at 23.86%[19]. - The number of A-share shareholders reached 101,006, while H-share shareholders totaled 88 as of the reporting period[23]. Business Growth and Investments - The company attributed the significant revenue growth to the integration of Minsheng Securities and increased performance in securities investment, brokerage, and investment banking businesses[14]. - The company has successfully acquired 99.26% of Minsheng Securities through the issuance of A-shares, enhancing its market position[24]. - The company reported a substantial increase in trading financial assets, which rose to RMB 65.69 billion from RMB 37.92 billion, a growth of about 73.5%[27]. - The company has made significant investments in long-term equity investments, which increased to RMB 82.33 million from RMB 77.37 million[27]. Other Financial Metrics - The weighted average return on net assets increased by 2.19 percentage points to 0.96% from -1.23%[6]. - The risk coverage ratio improved to 299.60% from 233.70% at the end of the previous year[10]. - The liquidity coverage ratio increased to 237.79% from 161.85% at the end of the previous year[10]. - Non-recurring gains and losses amounted to -¥1,355,400.58 after tax, indicating a focus on sustainable income sources[12]. - Goodwill increased dramatically by 1,131.60% to approximately ¥14.07 billion, reflecting the impact of newly acquired subsidiaries[16]. - The company experienced a significant increase in deferred tax assets, which rose by 2,056.16% to approximately ¥862.77 million, primarily due to the consolidation of new subsidiaries[16].

Financial Performance - For the first quarter of 2025, the company reported a revenue of RMB 256,762,012 thousand, representing a decrease of 6.61% compared to the same period last year[5]. - The net profit attributable to shareholders for the same period was RMB 5,150,787 thousand, down 14.51% year-over-year[9]. - The basic and diluted earnings per share were both RMB 0.34, reflecting a decline of 14.79% compared to RMB 0.399 in the previous year[9]. - Total revenue for Q1 2025 was $256,762,012, a decrease of 6.9% compared to Q1 2024's $274,948,792[41]. - Total operating costs for Q1 2025 were $248,963,871, down 6.4% from $265,942,631 in Q1 2024[41]. - Operating profit for Q1 2025 was $7,383,991, a decline of 14.7% from $8,654,646 in Q1 2024[42]. - Net profit for Q1 2025 was $6,101,010, down 13.9% from $7,092,243 in Q1 2024[42]. - Other comprehensive income after tax for Q1 2025 was $98,728, a decrease of 52.0% compared to $205,193 in Q1 2024[43]. - Total comprehensive income for Q1 2025 was $6,199,738, down 15.0% from $7,297,436 in Q1 2024[44]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 1,907,756,542 thousand, an increase of 2.41% from the previous year[11]. - Total liabilities rose to CNY 1,480,163,925 as of March 31, 2025, compared to CNY 1,440,245,700 as of December 31, 2024, marking an increase of approximately 2.8%[38]. - Current liabilities amounted to CNY 1,133,567,260 as of March 31, 2025, compared to CNY 1,112,754,359 at the end of 2024, showing a growth of around 1.9%[37]. - Non-current liabilities totaled CNY 346,596,665 as of March 31, 2025, up from CNY 327,491,341 as of December 31, 2024, representing an increase of about 5.8%[38]. - Shareholders' equity reached CNY 427,592,617 as of March 31, 2025, compared to CNY 422,596,822 at the end of 2024, reflecting a growth of approximately 1.2%[39]. Cash Flow - The net cash flow from operating activities showed a significant improvement, with a net amount of RMB -38,946,530 thousand compared to RMB -46,593,910 thousand in the previous year[9]. - Cash inflow from operating activities for Q1 2025 was CNY 278,047,473 thousand, down from CNY 291,632,380 thousand in Q1 2024, representing a decline of about 4.7%[47]. - Cash outflow from operating activities for Q1 2025 totaled CNY 316,994,003 thousand, compared to CNY 338,226,290 thousand in Q1 2024, indicating a decrease of approximately 6.3%[48]. - Cash inflow from investment activities for Q1 2025 was CNY 2,917,365 thousand, down from CNY 3,373,287 thousand in Q1 2024, a decrease of about 13.5%[49]. - Cash outflow from investment activities for Q1 2025 was CNY 13,523,008 thousand, compared to CNY 17,043,949 thousand in Q1 2024, reflecting a reduction of approximately 20.5%[49]. - Cash inflow from financing activities for Q1 2025 was CNY 118,631,004 thousand, an increase from CNY 107,716,826 thousand in Q1 2024, representing a growth of about 10.5%[49]. Contracts and Business Operations - The total amount of new contracts signed by the group in Q1 2025 was RMB 492.8453 billion, a decrease of 10.50% year-on-year[24]. - Domestic business new contracts amounted to RMB 448.6816 billion, accounting for 91.04% of the total, down 13.17% year-on-year[24]. - Overseas business new contracts reached RMB 44.1637 billion, representing 8.96% of the total, with a year-on-year increase of 30.10%[24]. - The new contract amount for the engineering contracting industry was CNY 3,710.135 million, a decrease of 18.72% year-on-year[26]. - The green environmental protection sector saw a new contract amount of CNY 490.055 million, with a significant year-on-year increase of 77.05% due to accelerated project acquisition and transformation efforts[26]. - The total new contract amount for the first quarter of 2025 was CNY 4,200.190 million, representing a year-on-year decrease of 13.25%[27]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 237,323[14]. - The top shareholder, China Railway Construction Group Co., Ltd., holds 6,956,316,590 shares, representing 51.23% of the total shares[18]. - HKSCC Nominees Limited holds 2,062,457,532 shares, accounting for 15.19% of the total shares[18]. - The company does not have knowledge of any relationships or concerted actions among the top ten shareholders and the top ten unrestricted shareholders[23]. Governance and Management - The company appointed new directors and management personnel during the recent shareholder meetings, indicating a strategic shift in governance[30][31][32].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,195,587, a decrease of 30.64% compared to CNY 1,723,183 in the same period last year[6] - Net profit attributable to shareholders for the same period was CNY 294,942, a significant decline from CNY 888,760 in the previous year[6] - The net cash flow from operating activities was negative CNY 21,458, indicating a decrease from positive CNY 308,131 in the previous year[6] - Basic and diluted earnings per share were both CNY -0.09, down from CNY -0.05 in the previous year[6] - The total comprehensive income attributable to the parent company for Q1 2025 was -294,942,888 RMB, compared to -173,760,528 RMB in Q1 2024[38] - The net profit for Q1 2025 was -312,347,004 RMB, compared to -223,170,760 RMB in Q1 2024, indicating a deeper loss year-over-year[35] - The operating profit for the period was -296,549,610 RMB, worsening from -171,656,846 RMB in the previous year[34] Assets and Liabilities - Total assets at the end of the reporting period were CNY 47,303,151, a decrease of 3.15% from CNY 48,841,884 at the end of the previous year[8] - Total liabilities as of March 31, 2025, were CNY 35,848,687,672, compared to CNY 37,074,445,175 as of December 31, 2024[28] - Total current liabilities were reported at 16,347,157,710 RMB as of March 31, 2025, an increase from 13,963,410,640 RMB at the end of December 2024, indicating a rise of about 17%[48] - The total assets as of March 31, 2025, were CNY 47,303,151,514, compared to CNY 48,841,884,791 as of December 31, 2024[30] - Current liabilities totaled CNY 18,940,982,161 as of March 31, 2025, an increase from CNY 16,251,327,379 as of December 31, 2024[27] Shareholder Information - Equity attributable to shareholders was CNY 9,404,199, a decrease of 3.04% from CNY 9,699,142 at the end of the previous year[8] - The largest shareholder, Beijing Beichen Industrial Group Co., Ltd., holds 1,174,169,731 shares, representing 34.87% of the total shares[15] - The second largest shareholder, HKSCC Nominees Limited, holds 691,318,399 shares, accounting for 20.53% of the total shares[15] Revenue and Sales - The company achieved a sales area of 91,300 square meters, a year-on-year increase of 101.10%[23] - The sales amount reached RMB 1.053 billion, reflecting a year-on-year increase of 63.51%[23] - The company's operating revenue for Q1 2025 reached RMB 453,589,667, an increase from RMB 394,916,593 in Q1 2024, representing a growth of approximately 14.8%[52] - Operating profit for Q1 2025 was RMB 120,927,923, compared to RMB 84,962,738 in Q1 2024, indicating a year-over-year increase of about 42.3%[53] - Net profit for Q1 2025 was RMB 90,433,586, up from RMB 64,066,759 in Q1 2024, reflecting a growth of approximately 41.2%[54] Cash Flow - Cash inflow from investment activities totaled 27,596,268 RMB in Q1 2025, down from 33,550,397 RMB in Q1 2024[44] - The company reported a significant increase in cash received from sales of goods and services, amounting to 1,592,123,152 RMB in Q1 2025, compared to 1,144,473,545 RMB in Q1 2024[42] - The company incurred operating expenses of 1,795,039,110 RMB in Q1 2025, slightly lower than 1,921,272,502 RMB in Q1 2024[43] - The ending cash and cash equivalents balance decreased to RMB 4,629,097,525 from RMB 5,653,976,506 in Q1 2024, reflecting a decline of 18.1%[61] Research and Development - Research and development expenses for Q1 2025 amounted to CNY 1,441,180, while there were no R&D expenses reported in Q1 2024[33] - Research and development expenses for Q1 2025 were RMB 131,812,923, compared to RMB 141,492,441 in Q1 2024, showing a decrease of about 6.8%[52] Future Plans - The company plans to expand its market presence and invest in new product development to drive future growth[51] - The company aims to enhance its operational efficiency and explore potential mergers and acquisitions to strengthen its market position[51]

Sales and Revenue Performance - In 2024, the company recorded revenue of approximately RMB 1,242.4 million, a decrease of about RMB 376.7 million or 23.2% compared to 2023[25]. - Vehicle sales (including new and used cars) amounted to approximately RMB 989.8 million, down 27.1% from RMB 1,357.0 million in 2023[16]. - New car sales revenue was approximately RMB 982.5 million (9,164 units), a decline of 26.8% from RMB 1,341.7 million (11,435 units) in 2023[17]. - The company sold 1,773 new energy vehicles, generating revenue of approximately RMB 201.5 million[17]. - Other comprehensive automotive services generated revenue of approximately RMB 252.6 million, a decrease of 3.6% from RMB 262.1 million in 2023[19]. - Revenue for 2024 was RMB 1,242,382 thousand, a decrease of 23.3% compared to RMB 1,619,147 thousand in 2023[192]. Profitability and Financial Metrics - The gross profit decreased by approximately 82.0% to RMB 16.2 million, with an overall gross margin of about 1.3% compared to 5.6% in the previous year[27]. - The annual loss was approximately RMB 90.2 million, compared to RMB 53.2 million in the previous year[33]. - The net loss for 2024 was RMB 90,151 thousand, compared to a net loss of RMB 53,245 thousand in 2023, representing an increase in losses of 69.5%[194]. - The basic and diluted loss per share for 2024 was RMB (17.76) compared to RMB (10.36) in 2023, indicating a worsening loss per share[192]. Market Trends and Strategic Focus - In 2024, the sales volume of new energy vehicles reached 40.9% of total new car sales in China, highlighting the growing demand for charging infrastructure[11]. - The automotive industry is expected to see a steady growth in sales due to government incentives and the increasing penetration rate of new energy vehicles, projected to exceed 50%[12]. - The company plans to focus on "new energy exploration," "new media marketing," "user value cultivation," and "operational efficiency upgrades" in 2025[12]. - The company aims to explore more "charging + retail" business models to enhance user stickiness and brand influence in the new energy infrastructure sector[11]. Operational Adjustments and Cost Management - The company closed unprofitable stores and optimized existing network management to adapt to the changing market landscape[10]. - Sales and distribution expenses decreased by approximately RMB 26.3 million or 33.8% to about RMB 51.4 million, mainly due to reduced employee and advertising costs in new businesses[29]. - Administrative expenses amounted to approximately RMB 80.7 million, a decrease of about RMB 8.4 million, primarily due to reduced rent and miscellaneous expenses[30]. - The company aims to enhance its business model and user operations while expanding its new energy vehicle sales and charging network in response to market challenges[24]. Corporate Governance and Compliance - The board has established mechanisms to ensure independent opinions and advice are available, maintaining a balance of skills and experiences[128]. - The company has adopted the corporate governance code and has maintained compliance since its listing, with the roles of chairman and CEO held by the same individual, which the board believes benefits management[124]. - The board is responsible for approving the group's development, business strategies, policies, and annual budgets[133]. - The company has established an internal audit and compliance department to conduct regular internal audits across major departments, including governance, environmental, social, operational, legal, and financial aspects[160]. Environmental and Social Responsibility - The company has implemented strict environmental protection measures to comply with current laws and regulations[57]. - The company encourages all employees to participate in environmental activities to benefit the community[58]. - The board considers environmental, social, and governance risks when making business decisions[165]. - The company has a clear anti-bribery and anti-corruption policy that guides employee conduct and response to bribery and corruption[165]. Shareholder Engagement and Dividends - The company reported a reserve available for distribution to shareholders of RMB 103,214,000 as of December 31, 2024, unchanged from 2023[69]. - The board does not recommend the payment of a final dividend for the fiscal year 2024, consistent with the previous year[63]. - The company maintains ongoing communication with shareholders to enhance their understanding of the business and performance[169]. - The company has reviewed its shareholder engagement for the 2024 fiscal year and found its communication policy to be effective[169]. Stock Options and Employee Incentives - The company has adopted a share option scheme allowing for the issuance of up to 50,000,000 shares, representing 10% of the shares issued at the time of the scheme's adoption[70]. - The total number of stock options granted to directors and employees amounted to 31,318,000, with 3,900,000 options having expired[78]. - The company has granted stock options to key executives, including 1,200,000 options at HKD 0.48 and 900,000 options at HKD 0.81, with various exercise dates[76]. - The company continues to monitor its stock option plan to ensure it remains competitive and effective in attracting and retaining talent[76]. Audit and Financial Reporting - The independent auditor's report confirms that the consolidated financial statements present a true and fair view of the group's financial position as of December 31, 2024[172]. - The auditors aim to obtain reasonable assurance that the consolidated financial statements are free from material misstatement due to fraud or error[184]. - The audit process involved identifying and assessing risks of material misstatement and designing audit procedures to address these risks[185]. - The overall presentation, structure, and content of the consolidated financial statements were evaluated for fairness and appropriateness[190].

Company Performance - The company reported a strong performance with a continuous presence in the top 50 global pharmaceutical companies for six consecutive years from 2019 to 2024[19]. - The company has been recognized as one of the top 50 best companies in Asia-Pacific by Forbes for three consecutive years from 2016 to 2018[16]. - The company recorded revenue of approximately RMB 28,866.16 million, representing a year-on-year growth of about 10.2% compared to RMB 26,199.41 million in the previous year[73]. - Gross profit was approximately RMB 23,529.94 million, an increase of about 10.9% from RMB 21,209.53 million in the previous year[73]. - Profit attributable to equity holders of the parent company was approximately RMB 3,499.83 million, reflecting a significant year-on-year increase of about 50.1%[74]. Financial Highlights - Total revenue for 2024 reached RMB 28,866,159 thousand, a 10.1% increase from RMB 26,199,409 thousand in 2023[26]. - Gross profit for 2024 was RMB 23,529,941 thousand, up from RMB 21,209,532 thousand in 2023, reflecting a gross margin improvement[26]. - Operating profit for 2024 was RMB 5,739,924 thousand, showing a significant increase compared to RMB 4,209,634 thousand in 2023[29]. - The company reported a net profit of RMB 6,364,682 thousand for 2024, compared to RMB 5,097,398 thousand in 2023, marking a 24.9% year-over-year growth[26]. - The total assets of the company reached RMB 65,408,069 thousand in 2024, up from RMB 63,604,819 thousand in 2023[26]. Research and Development - Research and development expenses for 2024 amounted to RMB 5,089,203 thousand, an increase from RMB 4,402,973 thousand in 2023, indicating a focus on innovation[26]. - The company has established multiple R&D centers recognized by Jiangsu Province, focusing on oncology and other therapeutic areas[12]. - The company is actively involved in expanding its market presence and enhancing its product offerings through strategic R&D initiatives[11]. - The company has 70 innovative drugs in development, including 39 for oncology, 7 for liver diseases, 13 for respiratory diseases, and 6 for surgical/pain relief[102]. Product Portfolio and Innovations - The company has a diverse product portfolio, including various biopharmaceuticals and chemical drugs, with a strong market position in oncology, liver disease, respiratory, and surgical/pain relief[11]. - The company plans to launch new innovative products within the next five years, focusing on original innovation rather than imitation[38]. - The company received approval for 6 innovative products from the NMPA, including 4 Class 1 innovative drugs, achieving a revenue of RMB 12.06 billion from innovative products in 2024, a year-on-year increase of 21.9%[46]. - Revenue from new products launched within the last 5 years reached RMB 10.09 billion in 2024, reflecting a year-on-year growth of 25.4%[46]. Market and Strategic Initiatives - The company aims to become a leading global pharmaceutical enterprise, emphasizing innovation and patient service[11]. - The government has implemented policies to encourage pharmaceutical innovation, which is expected to positively impact the company's growth trajectory[44]. - The company is actively pursuing multiple indications for Gosorese, aiming to establish it as a key product in the oncology field[50]. - The company is focusing on clinical research to provide more academic evidence for the clinical use of its products[56]. Corporate Governance and Management - The board of directors focuses on overall corporate strategy and financial performance, emphasizing sustainable development[123]. - The company has established various committees, including an executive committee and an audit committee, to enhance board efficiency and oversight[125]. - The company emphasizes compliance with legal and regulatory requirements in its governance practices[133]. - The company has adopted a code of conduct for securities trading by directors and senior management, ensuring compliance with the standards set forth in the Listing Rules[162]. ESG and Sustainability - The company received an MSCI ESG rating of A for two consecutive years and improved its S&P CSA score to the top 4% in the global pharmaceutical industry[121]. - The company has implemented a carbon neutrality goal and pathway plan, with annual sustainable energy usage continuously increasing and carbon emission density decreasing[117]. - The company invested a total of RMB 60.11 million in community initiatives, with community service hours totaling 3,213 hours during the year[120]. - The company achieved a 96% pass rate in supplier ESG management self-assessments, identifying 13 key risks and achieving a 100% improvement plan formulation rate[120].

Financial Performance - For the year ended December 31, 2024, the Group reported revenue of RMB1,252.6 million, marking a 7.1% decrease compared to the prior year[19]. - The loss attributable to owners of the Company amounted to RMB20.1 million, compared to a profit of RMB87.8 million in 2023, resulting in a loss per share of RMB0.014[19]. - The Group's total sales proceeds decreased by 11.8% to RMB2,782.3 million from RMB3,154.1 million in the previous year, with a year-on-year decrease of 12.1% in the second half of 2024[36]. - Gross profit for the year decreased by 10.6% to RMB702.0 million, while the gross profit margin as a percentage of total sales proceeds increased to 25.2% from 24.9% in 2023[37]. - The Group's adjusted EBITDA for the year decreased by 17.5% to RMB358.1 million from RMB434.3 million in 2023, primarily due to a decline in sales and revenue[54]. - The Group's share of Beiren Group's net profit decreased by 25.4% to RMB138 million from RMB185.0 million in 2023[88]. - The Group's revenue for 2024 was RMB1,252.6 million, a decrease of 7.1% from RMB1,349.0 million in 2023, with total sales proceeds dropping 11.8% to RMB2,782.3 million[40]. Strategic Initiatives - The Group celebrated the 20th anniversary of Shanghai Jiuguang in September 2024, emphasizing its commitment to a "Customer-First" philosophy and innovative service offerings[17]. - The Group has optimized tenant portfolios and diversified product categories to adapt to market shifts and enhance online and offline integration[18]. - The Group aims to enhance operational efficiency and capitalize on government initiatives to boost consumption and expand domestic demand[22]. - The Group plans to expand its membership base and refine its loyalty program, introducing exclusive privileges for new members[23]. - The Group's strategy includes optimizing merchandise assortments and enhancing omnichannel integration to adapt to evolving consumer preferences[32]. - The Group will leverage high-traffic social media platforms to enhance customer engagement through live streaming and interactive content[24]. - The Group's strategies included promoting scenario-based consumption and advancing green and low-carbon development to meet evolving consumer needs[71]. Market Conditions - The retail growth rate of offline stores has moderated across the industry, influenced by heightened consumer caution and competitive pressures from e-commerce[18]. - The Shanghai Municipal Government's campaigns, such as the "New Year Celebration Shopping Festival," align with the Group's initiatives to stimulate consumer spending[31]. - The retail landscape is shifting towards rational consumption and service-oriented spending, prompting the Group to prioritize innovation and strategic agility in its offerings[104]. Sustainability and Environmental Initiatives - The Group is committed to advancing green, low-carbon development initiatives as part of its strategic focus[18]. - The Group's commitment to sustainability and green consumption practices is part of its strategy to meet changing consumer demands[32]. - The Group focuses on measuring and reporting carbon reduction results and promoting waste reduction at source[140]. - The Group aims to set sustainable and measurable environmental protection targets[139]. - The Group is implementing energy-saving measures, including the use of LED lighting to reduce power consumption in stores and offices[161]. - The Group has established emission reduction targets to help decrease greenhouse gas emissions, supporting global ecosystem sustainability[181]. Employee and Labor Relations - The Group employed a total of 1,078 full-time staff as of December 31, 2024, down from 1,172 as of December 31, 2023, reflecting a decrease in staff headcount and bonuses[45]. - The Group regularly reviews employee remuneration packages to ensure competitiveness, referencing industry standards and employee performance[187]. - The employee turnover rate for the Group in the financial year 2024 was 1.47%[196]. - The Group emphasizes enhancing employees' knowledge and skills in safety through training programs[200]. - The Group has a comprehensive performance appraisal management regime to attract and retain outstanding talents, ensuring transparency and fairness[186]. Financial Position - As of December 31, 2024, the Group's net debt decreased to approximately RMB196.8 million from RMB405.4 million as of December 31, 2023, due to increased operating cash and dividends received[55]. - Cash and cash equivalents, bank deposits, and structured bank deposits amounted to approximately RMB2,953.3 million, an increase from RMB2,823.6 million as of December 31, 2023[56]. - The debt-to-equity ratio slightly decreased from 34.9% to 34.5% due to a reduction in bank borrowings[61]. - The outstanding loan amount under the 15-year financing facility was RMB3,238 million as of December 31, 2024, down from RMB3,278 million in the previous year[64]. Customer Engagement and Experience - The Group focused on enhancing online member engagement and optimizing its online marketplace, which included facilitating click-and-collect services[72]. - The Shanghai Jiuguang Center (JGC) hosted various thematic campaigns in 2024 to elevate customer experiences and stimulate spending[73]. - Average daily footfall increased by 9.9% year-on-year to approximately 34,300 visitors, and the stay-and-buy ratio improved by 0.9 percentage points to 76.2%[81]. Challenges and Risks - The Group's independent legal opinion indicated a very low probability of recovering outstanding receivables, which have been deemed irrecoverable since the full provision for bad debts was established in 2019[100]. - The Group actively assesses climate-related risks, including extreme weather events, and has developed internal guidelines for safety and operational continuity[180]. - The Group's management will monitor foreign currency exposure and consider measures to mitigate significant potential foreign currency risks if necessary[63].

Financial Performance - Revenue for 2024 reached HKD 4,421,609,000, a 37% increase from HKD 3,217,372,000 in 2023[27] - Net profit attributable to ordinary shareholders was HKD 347,783,000, reflecting a 73% growth compared to HKD 201,261,000 in the previous year[27] - Earnings per share increased by 71% to HKD 3.6 from HKD 2.1 in 2023[27] - Total assets grew by 21% to HKD 130,173,149,000 from HKD 107,535,153,000 in 2023[27] - The company declared a dividend of HKD 305,260,000, a 60% increase from HKD 191,078,000 in the prior year[27] - The return on equity improved to 2.3%, up from 1.4% in 2023, an increase of 0.9 percentage points[27] - The company maintained a dividend payout ratio of 88%, down from 95% in the previous year[27] - The company's net profit after tax for 2024 increased by 73% year-on-year, reaching HKD 348 million, compared to HKD 201 million in 2023[40] - Total revenue for 2024 rose by 37% to HKD 4.422 billion, up from HKD 3.217 billion in 2023[40] Revenue Sources - Commission and fee income increased by 26% to HKD 872 million, with brokerage commissions rising by 17% to HKD 512 million[40] - Interest income grew by 28% to HKD 2.314 billion, with fixed income securities interest income surging by 188% to HKD 553 million[40] - Net trading and investment income surged by 72% to HKD 1.236 billion, with financial product net income increasing by 20% to HKD 912 million[40] - Institutional investor services revenue skyrocketed by 90% to HKD 1.921 billion, driven by increased interest income and financial product net income[40] - Corporate financing services revenue rose by 61% to HKD 319 million, attributed to higher placement, underwriting, and sub-underwriting commissions[40] - Wealth management business revenue reached HKD 439 million, a year-on-year increase of 13%[42] - Wealth Management segment revenue increased by 3% year-on-year to HKD 1.919 billion, driven by a rebound in Hong Kong stock trading volume and growth in US stock trading[52] - Investment Management segment revenue increased by 72% year-on-year to HKD 264 million, mainly due to the strategic increase in low-risk, high-rated, and highly liquid fixed-income securities[52] Market and Economic Context - The Hang Seng Index increased by 17.67% over the year, closing at 20,059.95 points, marking a significant recovery[37] - The total amount raised from initial public offerings (IPOs) in Hong Kong reached approximately HKD 87.5 billion, a nearly 90% increase compared to 2023[37] - The outlook for 2025 indicates that global economic recovery faces challenges, particularly from US-China trade relations and geopolitical issues, which may impact Hong Kong's capital market[65] - The Chinese government plans to implement a series of robust policy measures to stabilize economic growth in 2025, which is expected to support economic development from multiple dimensions[65] Corporate Governance - The board emphasizes the importance of good corporate governance to maintain effective operations and long-term shareholder value, adhering to high standards of governance[67] - The board consists of eight members, including two executive directors, three non-executive directors, and three independent non-executive directors, ensuring a high level of independence[70] - The company is committed to enhancing its market value management through transparent information disclosure and active investor engagement[66] - The company will continue to promote a culture of compliance, integrity, professionalism, and prudence as part of its core values[69] - The board consists of more than one-third independent non-executive directors, exceeding the minimum independence requirements of the Listing Rules[75] Risk Management - The company emphasizes the importance of a robust internal control system to mitigate risks, including ESG risks, and regularly reviews its effectiveness[108] - The risk committee is responsible for overseeing the risk management system and ensuring its effectiveness, with discussions held with management regarding significant risks faced by the group[112] - The company has implemented a risk management framework that includes risk culture, risk appetite, and overall risk management processes[113] - The risk management framework consists of a three-tier system, with the Risk Committee authorized by the Board of Directors as the first tier[114] Employee and Diversity Initiatives - As of December 31, 2024, the group has a total of 623 employees across Hong Kong, Singapore, and Macau, with a female employee representation of 45%[63] - The company aims to maintain the current level of female employee representation and promote gender diversity in hiring practices[63] - The company has adopted a diversity policy for the board, aiming for balanced representation across various dimensions including gender and professional experience[99] Shareholder Engagement - The company maintains effective communication with shareholders and stakeholders through various channels to provide timely and transparent information[129] - The company held its annual general meeting on May 22, 2024, and two special meetings on July 5 and November 19, 2024[131] - Shareholders holding at least 5% of voting rights can request the board to convene a special meeting[132] - The company’s investor relations team is available for inquiries via email at ir@gtjas.com.hk[131] Related Party Transactions - The company has complied with the applicable disclosure requirements under the Listing Rules regarding related party transactions[189] - The company actively monitors transactions with Guotai Junan Group to ensure compliance with annual limits and agreements[190] - The company has established internal control measures to ensure that related party transactions are conducted at market prices or better, and that they are approved by relevant departments prior to execution[191] ESG Commitment - The company received an "A" rating from MSCI, Wind, and other organizations for its ESG practices, reflecting its commitment to sustainable operations and responsible management[199] - The company has identified several ESG challenges and opportunities, integrating these into its overall business strategy[199] - The ESG Committee comprises seven members, including an independent non-executive director, and is responsible for overseeing sustainability and ESG-related matters[117]

Financial Performance - Total revenue for the reporting period was approximately RMB 109.0 million, a decrease of 13.8% compared to RMB 126.4 million in the same period last year[98]. - Revenue from sales of flat plate denitration catalysts decreased by 8.5% to approximately RMB 53.5 million, primarily due to a 23.6% drop in average selling price[99]. - Revenue from sales of honeycomb denitration catalysts increased by 136.0% to approximately RMB 49.8 million, driven by a 204.5% increase in sales volume[100]. - Revenue from automotive denitration catalysts significantly decreased by 87.8% to approximately RMB 5.7 million, attributed to a substantial reduction in sales orders[101]. - Gross profit for the reporting period was approximately RMB 27.5 million, an increase of 12.2% compared to the previous year, due to increased production of honeycomb denitration catalysts[102]. - Administrative expenses rose by 57.1% to approximately RMB 26.4 million, mainly due to increased bonuses for senior management and overseas operational expenses[104]. - The current ratio decreased from 1.6 times to 1.3 times, and the quick ratio decreased from 0.5 times to 0.3 times, primarily due to an increase in customer advance payments[108]. - The debt-to-asset ratio increased to 2.7% from 1.2% in the previous year, mainly due to an increase in bank borrowings[111]. - The company recorded a net loss attributable to shareholders of approximately RMB 37.3 million, an increase of 46.8% from RMB 25.4 million in the previous year[106]. - Cash and cash equivalents as of December 31, 2024, were approximately RMB 18.1 million, down from RMB 44.3 million in the previous year[110]. - The group reported a net income attributable to shareholders of approximately RMB 11.7 million as of December 31, 2024, compared to RMB 4.5 million in 2023, indicating a significant increase in profitability[119]. Market and Product Development - The group's industrial catalyst segment maintained stable revenue and operations, with new contract amounts slightly increasing compared to 2023, achieving the group's set goals[14]. - The vehicle catalyst segment experienced a significant decline in natural gas vehicle OEM catalyst products, while the aftermarket catalysts remained stable but limited in total volume[14]. - The group plans to implement a contraction strategy for the vehicle catalyst segment by the end of 2024 to further reduce R&D and other expenses[14]. - For 2025, the group aims to continue reducing manufacturing costs and improving product gross margins through raw material procurement control and production process optimization[16]. - The group will focus on R&D for new industrial products, including high-porosity catalysts and low-temperature catalysts, among others[17]. - The group has established a foundation for overseas market expansion and aims for further breakthroughs in overseas contract amounts in 2025[18]. - The group has been increasing its market share in the domestic industrial catalyst market, which is currently stable and on the rise[18]. - The group plans to enhance market development efforts in emerging environmental industries, including waste incineration power generation and biomass power generation[95]. - The group aims to continue reducing manufacturing costs for mature products, building on the achievements made in 2024[95]. - The group has successfully installed and commissioned the corrugated plate catalyst production line, with orders already signed domestically and internationally[93]. - The group anticipates stable or slight growth in the de-NOx catalyst market outside of thermal power generation by 2025[89]. - The group will focus on developing new products, particularly in the areas of HCN catalysts and NHMC catalysts, to increase market share[95]. - The group has made strategic decisions to reduce R&D investments in the vehicle catalyst OEM market due to a significant decline in orders[94]. Corporate Governance - The board consists of six directors, including two executive directors, one non-executive director, and three independent non-executive directors[27]. - All directors are required to disclose their public company roles and significant commitments annually, ensuring they dedicate sufficient time and effort to the company's affairs[31]. - The board has a strong independence with over one-third of its members being independent non-executive directors, ensuring a balance of power and protection of shareholder interests[34]. - During the reporting period, all directors participated in training related to the Listing Rules and ongoing professional development to enhance their knowledge and skills[41]. - The board held a meeting with all independent non-executive directors without the presence of other directors to facilitate open discussions[33]. - The company has established formal and informal channels for independent non-executive directors to express their views confidentially when necessary[36]. - The board's composition includes experienced individuals, which effectively balances the power of the chairperson and executive director[31]. - The company has received independence confirmations from all independent non-executive directors, affirming their status as independent individuals[34]. - The board is responsible for determining business and investment plans, preparing annual budgets, and making profit distribution recommendations[31]. - The company encourages all directors to attend relevant training courses, with costs covered by the company[41]. - The company has established three board committees: Audit Committee, Remuneration Committee, and Nomination Committee to oversee specific areas of governance[47]. - The Audit Committee held two meetings during the reporting period to review the financial performance for the year ending December 31, 2023, and the interim results for the six months ending June 30, 2024[49]. - The Remuneration Committee also conducted two meetings to review the remuneration of executive directors and senior management, as well as the share option scheme[53]. - The company’s governance structure includes a non-executive director and three independent non-executive directors to provide independent opinions[42]. - The company’s board believes that having the roles of Chairman and CEO combined under Zhao Shu provides strong and stable leadership[42]. - All executive directors have service contracts for three years, with a notice period of at least three months for termination[43]. - The company’s governance policies and practices are regularly reviewed to maintain high standards of corporate governance[45]. - The Audit Committee is responsible for providing independent opinions on the effectiveness of the group’s financial reporting procedures and internal controls[48]. - The company ensures compliance with legal and regulatory requirements through regular monitoring and review of policies and practices[45]. - The Nomination Committee held two meetings during the reporting period, with all members present, to assess the independence of non-executive directors and recommend the appointment of Dr. Wang Xueqian[56]. - The company has adopted a board diversity policy to ensure a balance of skills, experience, and perspectives[72]. - The board consists of at least one female director and at least one independent non-executive director with accounting or professional qualifications, ensuring diversity and compliance with governance standards[59]. - The company has set measurable targets for board diversity, which have been achieved during the reporting period[56]. - The external internal control audit function was outsourced to save costs, with the effectiveness of the internal control system audited annually[67]. - The board currently has two female directors, achieving gender diversity in compliance with Listing Rule 13.92[73]. - The gender ratio among employees, including senior management, is 78% male and 22% female as of December 31, 2024[73]. - The company plans to provide comprehensive training for female employees to prepare them for senior management and potential board succession[73]. Compliance and Risk Management - The company has implemented a whistleblowing policy to maintain transparency and accountability, with no significant fraud or misconduct incidents identified during the reporting period[69]. - The board has reviewed the effectiveness of risk management and internal control measures for the year ending December 31, 2024, ensuring compliance with established procedures and guidelines[68]. - The company has established a policy to promote and support anti-corruption laws and regulations, requiring employees to adhere to ethical standards and conduct[71]. - The company maintains compliance with applicable laws and regulations, with a compliance committee regularly reviewing policies and measures[133]. - The board is responsible for the risk management and internal control systems, which are reviewed annually for effectiveness, ensuring assets are protected from misappropriation and unauthorized allocation[64]. Shareholder Relations - Shareholders holding at least 10% of the paid-up capital have the right to request a special general meeting[77]. - The company encourages shareholder participation in meetings and allows proxy voting for those unable to attend[84]. - The company has reviewed its shareholder communication policy and believes it has been effectively implemented[81]. - The company ensures compliance with all applicable rules and regulations through its company secretaries[75]. - The company is committed to providing clear and accessible information to shareholders and stakeholders through various communication channels[81]. Employee Development - The group has implemented an employee stock option plan since October 14, 2015, to reward and incentivize eligible participants contributing to business success[134]. - The group has established an annual training program for employees to enhance their skills and ensure new hires acquire essential competencies[126]. - The group emphasizes the importance of employee skills and contributions for growth, investing resources in training and development[126]. Strategic Initiatives - The group utilized approximately 30% of the net proceeds from the share subscription (RMB 1,008,826.6) for the development of coating products, 50% (RMB 1,681,377.6) for expanding overseas markets, and 20% (RMB 672,551.0) for general working capital[118]. - The group plans to establish sales offices in China and Europe to expand its sales network, with an investment of RMB 6.9 million allocated for this purpose[114]. - The group has no significant contingent liabilities, guarantees, or litigation as of December 31, 2023, and 2024[123]. - The group has no major investments or acquisitions planned beyond those disclosed in the report[124]. - The share subscription price was set at HKD 0.048 per share, representing a discount of approximately 4.0% compared to the market price on the subscription agreement date[117]. - The group aims to optimize its capital structure and reduce financial risk through the proceeds from the share subscription[117]. Management and Leadership - The company has a strong management team with members holding advanced degrees and significant industry experience, enhancing strategic planning and execution capabilities[194][195][196]. - The management team includes professionals with backgrounds in investment banking and project management, which supports the company's strategic growth initiatives[195][198]. - The company has established a strong foundation for future growth by leveraging its experienced leadership and innovative capabilities[194][200]. - The company is focused on expanding its market presence and enhancing its product offerings through ongoing R&D efforts[200]. Research and Innovation - The company has been involved in over 30 research projects, including national key R&D programs, indicating a strong commitment to innovation and technology development[200]. - The company has published over 150 research papers, with significant contributions to environmental engineering and resource utilization, showcasing its expertise in sustainable practices[200]. - The company has received multiple awards for its research achievements, including a second-class national technology invention award, reflecting its impact on the industry[200]. - The company is committed to sustainable development, as evidenced by its research in low-carbon technologies and waste management[200].

Financial Performance - Jiangsu Qunxin Biopharmaceutical Co., Ltd. achieved a revenue of approximately RMB 158.8 million in 2024, marking a significant increase compared to 2023[14]. - The company reported a net loss of RMB 349.7 million for the year, an improvement from a loss of RMB 521.3 million in 2023, indicating a reduction in losses by approximately 32.9%[14]. - Cash and cash equivalents increased by 47.6% to RMB 556.1 million, up from RMB 376.7 million in 2023, reflecting a strong liquidity position[14]. - The adjusted net loss under non-IFRS measures was RMB 274.2 million, down from RMB 390.0 million in 2023, indicating improved operational efficiency[14]. - For the fiscal year ending December 31, 2024, the company's revenue was RMB 158.8 million, primarily from licensing fees of RMB 100.9 million from QX008N and QX004N, and RMB 55.7 million from R&D and CDMO services[15]. - The company's CDMO service revenue increased from RMB 12.1 million in 2023 to RMB 23.8 million in 2024, reflecting a growth of RMB 11.7 million[15]. - The cost of sales for the fiscal year ending December 31, 2024, was RMB 66.6 million, which includes costs associated with R&D services for QX004N and QX008N, as well as CDMO services[16]. - The company achieved a gross profit of RMB 92.2 million for the fiscal year ending December 31, 2024, with a gross margin reflecting strong R&D capabilities[55]. - The company's total employee costs, including director remuneration, amounted to approximately RMB 168.8 million for the year ending December 31, 2024, a decrease from RMB 222.4 million for the previous year[51]. - Administrative expenses decreased significantly from RMB 164.6 million in 2023 to RMB 115.9 million in 2024, mainly due to a reduction in equity-settled share payment expenses[61]. - Other income increased by 15.63% from RMB 24.9 million in 2023 to RMB 28.8 million in 2024, driven by government subsidies and interest income[59]. - Financial costs rose by 39.3% to RMB 23.4 million in 2024, attributed to increased bank borrowings to meet operational needs[63]. - The company recorded a net loss of RMB 349.7 million for the year ending December 31, 2024, an improvement of 33% compared to a net loss of RMB 521.3 million in 2023[64]. - The company has generated significant operating losses since its inception and expects to continue incurring losses for the foreseeable future[164]. Research and Development - The company’s R&D expenses decreased to RMB 334.3 million from RMB 364.4 million in the previous year, showing a focus on cost management[14]. - R&D expenses decreased by 8.3% from RMB 364.4 million in 2023 to RMB 334.3 million in 2024, mainly due to reclassification of clinical costs and a reduction in equity-settled share payment expenses[17]. - The total R&D costs for the year ended December 31, 2024, amounted to approximately RMB 334.3 million, a decrease from RMB 364.4 million in 2023[46][47]. - The company has achieved 20 IND approvals over the past 9 years, with 19 from the National Medical Products Administration and 1 from the FDA[45]. - QX002N for AS is progressing to Phase III clinical trial, with primary endpoint data expected in February 2025[27]. - QX005N for adult moderate-to-severe AD and PN has initiated Phase III trials, with first patient in (FPI) achieved in May 2024[27]. - QX001S received drug registration certificate from the National Medical Products Administration in October 2024, branded as "Sailuxin®"[27]. - QX004N completed Phase II primary endpoint data readout in August 2024, with further clinical trial plans announced[27]. - QX006N for SLE completed Phase Ib clinical trial as of the last feasible date[27]. - QX005N has received IND approvals for seven indications, including adult and adolescent moderate-to-severe AD, PN, and asthma[28]. - QX013N for CSU achieved the last patient in (LPI) for Phase I clinical trial in September 2024[27]. - The company has established a collaboration agreement with East China Pharmaceutical for the development and commercialization of QX001S in China[27]. - QX008N is under development for COPD in China, with Health元 leading the clinical trials[27]. - The company retains exclusive rights for QX001S outside of China, while collaborating with East China Pharmaceutical for its commercialization[27]. - QX005N was included in the Breakthrough Therapy Designation (BTD) list in January 2024, indicating superior clinical efficacy compared to current treatments[29]. - The Phase II clinical trial for QX005N in treating CRSwNP was completed in February 2025, with a collaboration agreement established with China Meheco in July 2024 for joint development[30]. - The Phase III clinical trial for QX002N in treating AS enrolled 641 patients, with a 40.4% ASAS40 response rate in the treatment group compared to 18.9% in the placebo group (P<0.0001)[32]. - QX001S, a biosimilar to ustekinumab, was approved in October 2024, with global sales of Stelara® reaching $10.361 billion in 2024[34]. - China Meheco submitted a BLA for QX001S in July 2023, which was approved in October 2024, and additional applications for pediatric indications are underway[35]. - QX004N showed a 76.9% improvement in PASI scores after 16 weeks of treatment in the Phase II trial, indicating strong efficacy[37]. - QX008N completed its Phase Ib clinical trial for moderate to severe asthma in January 2025, with a licensing agreement signed with Health元 for development in specific regions[39]. - QX013N received clinical trial approval from the National Medical Products Administration for the treatment of CSU on May 9, 2024, marking it as the first c-kit targeted candidate biologic in China[40]. - QX006N, an IFNAR1 targeted monoclonal antibody for SLE, successfully completed its Ib phase clinical trial in October 2024[43]. Strategic Collaborations and Partnerships - Strategic collaborations with major pharmaceutical companies were established to enhance clinical research and commercialization potential, including partnerships for QX008N and QX004N[9]. - The company entered into a strategic collaboration with Health Yuan for the development and commercialization of QX008N, receiving an upfront payment of RMB 75.0 million[20]. - A collaboration agreement was established with Han Sen (Shanghai) for QX004N, which includes potential milestone payments of up to RMB 1,032.0 million[21]. - The company will share the costs of the Phase III clinical trial for QX005N with China Medical East on a 50/50 basis, enhancing its commercialization potential[22]. - The company has a strategic focus on product licensing and mergers and acquisitions, as highlighted by Mr. Yu's previous role in business development at Heplisav-B[113]. - The company aims to enhance its market presence through strategic partnerships and collaborations in the biopharmaceutical sector[117]. Market and Operational Strategies - Future strategies will focus on maintaining clinical progress of existing products and expanding into domestic and international markets for innovative drugs[11]. - The company plans to strengthen its core competitive advantages by expanding its pipeline and seeking overseas opportunities[52][53]. - The company aims to enhance production efficiency and capacity utilization while continuing to recruit and develop talent[53]. - The company has a mission to address the vast unmet medical needs in the autoimmune and allergic disease market through its innovative therapies[157]. - The company has a strong focus on expanding its market presence and enhancing its product development capabilities[157]. - The company is positioned for future growth with a focus on innovation and market expansion, supported by its experienced leadership team[123]. Governance and Management - The board currently consists of three executive directors, two non-executive directors, and three independent non-executive directors[155]. - The independent directors are tasked with providing oversight and strategic guidance, ensuring the company's governance aligns with best practices[121][126]. - The management team emphasizes the importance of financial reporting and analysis in driving business decisions and strategies[110]. - The company is committed to ensuring no actual conflicts of interest exist between its directors and stakeholders[116]. - The company has a diverse board with members experienced in finance, investment management, and biopharmaceuticals, enhancing its strategic oversight[136]. - The management team has a diverse background in pharmaceuticals, biotechnology, and clinical research, contributing to strategic growth[142]. Risks and Compliance - The company faces significant risks related to its financial condition, drug development, clinical trials, and regulatory approvals, with no guarantee of successfully commercializing its core products[163]. - The company is committed to maintaining compliance with environmental protection and occupational health and safety regulations in China[166]. - The group regularly monitors liquidity needs and adheres to borrowing covenants to maintain sufficient cash reserves[87]. - The group conducts impairment assessments based on expected credit loss models to ensure adequate provisions for credit losses[86]. Employee and Operational Metrics - As of December 31, 2024, the company employed 339 staff members, all located in China, and is focused on providing a safe working environment[171]. - The internal R&D team consists of 125 members, with approximately 59% holding master's degrees or higher in relevant fields[45]. - The production facility has passed GMP compliance inspection by the National Medical Products Administration in November 2024, ensuring adherence to quality standards[48]. - The production facility has a therapeutic antibody production capacity of approximately 300 kg per year, with specific production lines for vials and pre-filled syringes[48]. Financial Position and Investments - Current assets increased from RMB 418.3 million in 2023 to RMB 616.7 million in 2024, reflecting a significant growth in liquidity[66]. - Trade and other receivables surged by 95.8% from RMB 26.5 million in 2023 to RMB 51.8 million in 2024, driven by increased receivables from licensing agreements[71]. - Non-current liabilities rose by 37.0% from RMB 242.9 million in 2023 to RMB 332.7 million in 2024, mainly due to an increase in bank loans with a term of 2 to 3 years[69]. - The company's operating cash flow improved, with net cash used in operating activities decreasing from RMB 300.7 million in 2023 to RMB 186.1 million in 2024[76]. - Financing activities generated net cash of RMB 351.8 million in 2024, a significant increase from RMB 61.2 million in 2023, largely due to IPO proceeds and increased bank borrowings[77]. - The current ratio decreased from 1.7 in 2023 to 1.4 in 2024, attributed to rising current liabilities associated with ongoing clinical trials[82]. - The debt-to-asset ratio increased from 42.5% in 2023 to 74.7% in 2024, primarily due to higher bank borrowings[83]. - The company has an unused credit line of RMB 161.7 million available for working capital as of December 31, 2024[75]. - The group has implemented a cautious investment strategy, focusing on low-risk financial products provided by reputable banks[96].

Financial Performance - Revenue for 2024 reached $1,507,767 thousand, representing a 43.0% increase compared to $1,054,092 thousand in 2023[11] - Gross profit for 2024 was $316,347 thousand, up 45.6% from $217,291 thousand in 2023[11] - Net income for 2024 was $13,811 thousand, a decrease of 25.7% from $18,588 thousand in 2023[11] - Adjusted EBITDA for 2024 was $138,254 thousand, reflecting a 31.3% increase from $105,270 thousand in 2023[11] - Adjusted net profit for 2024 was $49,342 thousand, a significant increase of 158.1% compared to $19,120 thousand in 2023[11] Assets and Liabilities - Current assets as of December 31, 2024, totaled $504,206 thousand, an increase from $400,204 thousand in 2023[9] - Current liabilities increased to $581,326 thousand in 2024 from $356,563 thousand in 2023[9] - As of December 31, 2024, the total assets of the company amounted to $814.7 million, an increase from $691.6 million as of December 31, 2023, representing a growth of 17.8%[148] - The total liabilities increased to $592.3 million as of December 31, 2024, compared to $432.4 million as of December 31, 2023, resulting in a debt-to-asset ratio of 72.7%, up from 62.5%[148] - Cash and cash equivalents reached $167.8 million as of December 31, 2024, compared to $146.3 million as of December 31, 2023, reflecting a growth of 14.1%[150] Market Trends and Projections - The company anticipates that the market for industry-specific AI will exceed the traditional software market by more than ten times[12] - The integration of industry intelligence and data is expected to significantly enhance organizational efficiency and reduce operational costs[12] - The overall economic benefits from reduced operational costs are projected to outweigh the increased IT spending[12] - The total addressable market (TAM) for advertising and marketing is expected to exceed 20% of the entire advertising industry scale once AI capabilities reach autopilot[13] - The global advertising market is projected to exceed $650 billion in 2024, with a 6% year-over-year increase in social media app usage time[20] Revenue Streams and Growth - Mobvista achieved a record revenue growth of 43% year-over-year, increasing from $1.054 billion to $1.508 billion[13] - In-app purchases and subscription revenues are expected to grow by 13% year-over-year, reaching $150 billion globally in 2024[20] - The Ad-tech segment, centered around Mintegral, accounts for over 90% of the company's total net income, while the Mar-tech segment is still in the early stages of product development[35] - The company has expanded its market presence by covering approximately 130 countries and regions, with significant revenue contributions from the Asia-Pacific region (48%) and other regions (43%) in 2024[30] - The company aims to drive high-quality growth by leveraging accumulated data and optimizing marketing strategies through its marketing technology[34] Advertising Technology and Platforms - The Mintegral platform has become one of the leading third-party programmatic advertising trading platforms globally, contributing significantly to the company's revenue and profit[23] - The company has implemented a SaaS tool matrix strategy since 2019, integrating Ad-tech and Mar-tech capabilities to cover various stages of developer growth and optimize marketing solutions[34] - The company’s advertising alliance platform, established in 2013, continues to maintain a leading position in the industry, focusing on serving Chinese apps going global[31] - The company has helped over 10,000 global top advertisers and over 100,000 leading applications acquire quality users on a large scale in global markets[33] - The smart bidding product has contributed over 70% of Mintegral's total revenue since its launch, reflecting its growing importance in the company's revenue stream[69] Operational Efficiency and Cost Management - The gross margin is influenced by server costs and platform algorithm efficiency, with expectations to reduce server costs as scale increases and improve gross margins through enhanced data throughput[41] - The company’s total bank loans and overdrafts amounted to $85.0 million as of December 31, 2024, compared to $81.5 million as of December 31, 2023[150] - The accounts receivable turnover days improved to 44 days in 2024, down from 51 days in 2023[135][136] - The accounts payable turnover days remained stable at 86 days for both 2024 and 2023[137][138] - The company’s floating rate borrowings had an effective interest rate ranging from 3.4% to 7.9% during the reporting period[149] Research and Development - Research and development expenses rose by 61.5% to $152.3 million, driven by increased model training costs for smart bidding systems[127] - The R&D team consists of experts from top universities and companies, enhancing Mintegral's technical capabilities and industry standing, particularly in the light gaming sector[52] - The company aims to establish itself as a "Growth Hub" for developers, focusing on Ad-tech and Mar-tech ecosystems to assist small and medium-sized developers in achieving growth[74] - The marketing technology segment saw a year-on-year revenue growth of 12.3%, indicating ongoing development and optimization efforts[70] - The Mar-tech product system is being upgraded to enhance service capabilities, with 97% of traffic currently coming from overseas markets, indicating a strong global presence[77] Employee and Corporate Governance - As of December 31, 2024, the group has 711 full-time employees, a decrease from 739 employees as of December 31, 2023[158] - 57.7% of the full-time employees, or 410 individuals, are engaged in research and development activities[158] - The board of directors includes executive directors and independent non-executive directors, with Mr. Duan Wei as the chairman and Mr. Cao Xiaohuan as the CEO[200] - The company has not disclosed any significant risks or uncertainties faced during the reporting period[190] - No arrangements were made for directors to gain benefits through the purchase of company shares or bonds during the fiscal year ending December 31, 2024[199]